Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases acid production in the stomach.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **GERD (symptomatic):** 20 mg orally once daily for up to 8 weeks.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be adjusted based on clinical response. Doses up to 240 mg daily have been administered intravenously.
## Pediatric Dosing
* **Erosive Esophagitis (1 to 5 years):** 10 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (5 to 16 years):** 20 mg orally once daily for up to 8 weeks.
* **Note:** Dosing for pediatric patients can vary significantly based on weight and indication. Always refer to specific pediatric guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally or 40 mg intravenously once daily.
* **Renal Impairment:** No dose adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, headache, nausea, abdominal pain, dizziness, flatulence.
* **Serious:** Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia (potentially leading to cardiac arrhythmias, seizures), vitamin B12 deficiency, fundic gland polyps.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH:** Pantoprazole can decrease gastric acidity, affecting absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, and certain antiretrovirals (e.g., rilpivirine, atazanavir).
* **Methotrexate:** PPIs may increase methotrexate levels; monitor for toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential for increased levels of drugs metabolized by this enzyme (e.g., clopidogrel, though clinical significance is debated).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, tetany, seizures, arrhythmias).
* Monitor for signs of C. difficile infection.
* Long-term use: Consider monitoring vitamin B12 levels and bone mineral density.
## Clinical Pearls
* Pantoprazole is available as delayed-release oral tablets and as a powder for injection.
* Intravenous administration is generally reserved for patients unable to take oral medication.
* While generally well-tolerated, prolonged use of PPIs is associated with increased risks of certain adverse events.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before making any clinical decisions.
